Clinical Trial Update: DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating DA-EPOCH-R induction followed by nivolumab consolidation in newly diagnosed high-grade B-cell lymphoma with MYC, BCL2, and/or BCL6 rear…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade B-cell Lymphoma
• Lymphoma B-cell
• Non-hodgkin Lymphoma

Drugs mentioned

• DA-EPOCH-R
• nivolumab (nivolumab)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: Non Hodgkin Lymphoma, Lymphoma, B-Cell | Phase 2 | Status: ACTIVE_NOT_RECRUITING